Related by context. All words. (Click for frequent words.) 61 dose cohort 60 dosing cohort 60 bolus dose 59 doxorubicin docetaxel 59 dose regimens 58 dosage regimens 58 dose cohorts 58 ascending dose 58 dose escalation 57 DLTs 57 mg/m2 dose 57 hypofractionated 57 dosing cohorts 57 #mg/m# [001] 57 intradermal injections 56 liposome formulation 56 #mg/m# [002] 56 hematologic toxicity 56 paclitaxel poliglumex 56 peg interferon 56 intravitreal injection 56 mg kg dose 56 ascending doses 56 mg/m2/day 56 immunomodulatory therapy 56 pain palliation 56 bolus injection 56 im peramivir 56 ribavirin RBV 56 piperacillin tazobactam 56 CIMZIA TM 56 timepoints 55 subcutaneous infusion 55 continuous intravenous infusion 55 budesonide foam 55 intravenous IV infusion 55 recurrent glioblastoma multiforme 55 forodesine 55 micafungin 55 intradermal injection 55 double blinded placebo 55 administered subcutaneously 55 celgosivir 55 IV bolus 55 viral kinetics 54 pharmacodynamic PD 54 haematologic 54 Moli# 54 thorough QT 54 phase Ib 54 mitomycin 54 Phase IIb clinical trials 54 LEP ETU 54 BrachySil TM 54 q#h 54 intravesical 54 certolizumab 54 multicenter randomized placebo controlled 54 dosed orally 54 inhaled iloprost 54 doxorubicin cyclophosphamide 54 subcutaneous SC 54 fosbretabulin 54 relapsed MM 54 carboplatin paclitaxel 54 caspofungin 54 telaprevir dosing 54 XEPLION R 54 clevidipine 54 intermittent dosing 53 active comparator 53 amphotericin B 53 dose titration 53 dose cyclophosphamide 53 timepoint 53 systemic corticosteroids 53 rt PA 53 CHOP chemotherapy 53 rFSH 53 4mg/kg 53 randomized blinded 53 Q#IR 53 phase IIb clinical 53 PRESEPT study 53 fluticasone furoate 53 ALGRX 53 ibandronate 53 DMARD therapy 53 mg m² 53 eculizumab therapy 53 clinical pharmacology studies 53 biochemical relapse 53 treprostinil 53 PREZISTA r 53 prospectively defined 53 nab paclitaxel 53 Dose escalation 53 docetaxel Taxotere ® 53 TURBT 53 anti Xa 53 GnRH agonist 53 biologic DMARD 53 placebo controlled clinical 53 blind placebo 53 riociguat 53 huN# DM1 53 maximal dose 53 ritonavir boosted protease inhibitor 53 PEGPH# 53 intravenous cyclophosphamide 53 deferiprone 53 pharmacokinetic PK 53 PSMA ADC 52 pegfilgrastim 52 mg/m2 cohort 52 subcutaneous injections 52 GAMMAGARD 52 pegylated interferon alfa 52 melphalan prednisone 52 tobramycin 52 docetaxel chemotherapy 52 octreotide LAR 52 dosing interval 52 GnRH antagonist 52 injected subcutaneously 52 MoxDuo IR 52 Cloretazine 52 subcutaneous enoxaparin 52 plasma uric acid 52 intravenous dosing 52 salmeterol fluticasone 52 multidose 52 oral rivaroxaban 52 zonisamide SR 52 weekly subcutaneous injections 52 Peg IFN 52 ACAPODENE 52 DACH platinum 52 Phase IIa trials 52 CBLC# 52 lanthanum carbonate 52 AGILECT R 52 CHAMPION PCI 52 lamivudine resistant 52 deferoxamine 52 HuMax EGFr 52 Phase Ib II 52 Phase #b/#a 52 gadobutrol 52 Solazed 52 Panzem R NCD 52 oral deforolimus 52 sitaxsentan 52 dose escalation study 52 phase IIb study 52 lesional 52 ARIKACE 52 HCD# [002] 52 #mg QD [001] 52 dosage regimen 52 Pegasys ® 52 Omacetaxine mepesuccinate 52 RSD# oral 52 atazanavir ritonavir 52 pharmacodynamics PD 52 dose regimen 52 tacrolimus ointment 52 oral ibandronate 52 MoxDuo TM IR 52 Twinrix 52 vidofludimus 52 intra articular injections 52 rALLy clinical trial 52 neurologic progression 52 intramuscular injections 52 Tarceva TM 52 antiarrhythmic drug 51 pimecrolimus cream 51 receptor tyrosine kinase inhibitor 51 bicifadine 51 INACTINE TM 51 boosted protease inhibitor 51 subcutaneous doses 51 histrelin 51 complete cytogenetic response 51 therapeutic regimens 51 urinary N telopeptide 51 systemically administered 51 treatment naive genotype 51 subcutaneous dosing 51 IFN alfa 51 oral prednisone 51 KAPIDEX 51 Phase IIIb clinical 51 flutamide 51 alkylating agent 51 metered dose inhaler MDI 51 alfa 2a 51 pharmacokinetic PK study 51 EVIZON 51 alvespimycin 51 #mg dose [002] 51 dosing 51 #beta estradiol 51 Allovectin 7 51 subcutaneous insulin 51 protease inhibitor PI 51 chemotherapeutic regimens 51 CANCIDAS 51 noninferiority 51 dosing regimens 51 NP2 Enkephalin 51 favorable pharmacokinetic profile 51 mesalamine granules 51 Phase #b/#a trial 51 Targretin capsules 51 Augment Injectable 51 Pegasys plus Copegus 51 PrandiMet TM 51 ritonavir boosted 51 platelet inhibitor 51 lenalidomide dexamethasone 51 pegnivacogin 51 μg kg 51 PEGylated interferon 51 preclinical efficacy 51 subcutaneously administered 51 peg IFN 51 REG1 51 daunorubicin 51 maximally tolerated dose 51 macrolide antibiotic 51 systemic ALCL 51 nitrofurantoin 51 VP# [004] 51 MAS XR 51 oral levofloxacin 51 oral talactoferrin 51 ancrod 50 dalteparin 50 desvenlafaxine succinate 50 ABSSSI 50 FOLPI 50 INVEGA SUSTENNA 50 nicardipine 50 prostate cancer CaP 50 pegIFN 50 TLK# 50 #μg [002] 50 MGd 50 vinorelbine 50 octreotide 50 SCH # 50 mcg BID 50 IntroductionThe 50 generation purine nucleoside 50 prespecified 50 analgesic efficacy 50 Chemophase 50 GLP toxicology studies 50 postexposure 50 oral renin inhibitor 50 MDS AML 50 erythropoietic 50 cilengitide 50 relapsed MCL 50 xanthine oxidase inhibitor 50 SCIg 50 QD dosing 50 phase IIb trial 50 Insulin PH# 50 rindopepimut 50 ketorolac 50 virologic response EVR 50 systemic hypotension 50 TheraCIM h R3 50 Cleviprex TM clevidipine 50 plus ribavirin 50 mg QD 50 antimicrobial prophylaxis 50 daily subcutaneous injections 50 randomized #:#:# 50 NOX E# 50 mg administered orally 50 intravenously administered 50 pegylated interferon alfa 2a 50 mg kg IV 50 obatoclax 50 pharmacodynamic profile 50 pharmacokinetic characteristics 50 virologic response 50 APRISO 50 fluticasone salmeterol 50 MIRCERA 50 pharmacokinetics PK 50 APTIVUS 50 Phase Ib study 50 granisetron 50 amoxicillin clavulanate 50 methotrexate therapy 50 Phase III randomized controlled 50 Actilon 50 NATRECOR ® 50 #mg/day [001] 50 hypomagnesemia 50 lintuzumab SGN 50 CRMD# 50 VITAL Trial 50 MAGE A3 ASCI 50 dosing schedules 50 pyridostigmine 50 bolus dosing 50 epoetin alpha 50 mcg kg 50 LPV r 50 teriflunomide 50 antiretroviral regimen 50 LEXIVA r 50 randomized multicenter Phase III 50 lymphoid blast 49 demonstrated antitumor activity 49 pharmacologically active isomer 49 taxotere 49 corticosteroid dexamethasone 49 rFVIIa 49 5-FU/LV 49 unfractionated heparin 49 proton pump inhibitor PPI 49 efficacy tolerability 49 oral methylnaltrexone 49 isatoribine 49 pharmacokinetic profiles 49 antiemetics 49 multicenter Phase II 49 corticosteroid therapy 49 μg dose 49 cranial radiation 49 Enhanze Technology 49 budesonide formoterol 49 anticoagulation therapy 49 Evoltra ® 49 pyrazinamide 49 clopidogrel therapy 49 mg/m2 49 AZX# 49 APTIVUS r 49 Capesaris 49 Phase 1b trial 49 formoterol fumarate 49 warfarin therapy 49 revision hip arthroplasty 49 PEARL SC 49 confirmatory clinical 49 OvaRex ® MAb 49 posttreatment 49 omacetaxine mepesuccinate 49 antiandrogen 49 ACTILON 49 dose placebo controlled 49 dorzolamide 49 Zemplar Capsules 49 premixed insulin 49 analgesic medications 49 CIMZIA ™ 49 Phase #b/#a clinical 49 C conjugate vaccine 49 vernakalant hydrochloride 49 blinded randomized placebo controlled 49 trastuzumab Herceptin ® 49 pramlintide metreleptin combination 49 rHuPH# 49 paroxysmal AF 49 q8h 49 inhaled tobramycin 49 intravenous infusions 49 uric acid lowering 49 oral diclofenac 49 elacytarabine 49 gout flares 49 relapsed refractory 49 Triapine R 49 CYT# potent vascular disrupting 49 oxymorphone ER 49 remission induction 49 nucleoside analog 49 subcutaneous formulation 49 glatiramer acetate 49 peginterferon alfa 2b 49 oral iron chelator 49 premedication 49 telomerase inhibition 49 rhIGF-I/rhIGFBP-3 49 antiviral efficacy 49 Mycophenolate mofetil 49 BeneFIX 49 nitazoxanide 49 oral prodrug 49 placebo controlled clinical trials 49 Helicobacter pylori eradication 49 cannabinor 49 brivaracetam 49 PhG alpha 1 49 #mg BID [001] 49 DAPT 49 tipranavir r 49 placebo controlled studies 49 tumor regressions 49 β blockers 49 Plenaxis TM 49 severe oral mucositis 49 Prosaptide 49 Fibrillex TM 49 IMC A# 49 virological response 49 ASCT 49 subcutaneous dose 49 Q2W 49 ug kg 49 #μg [001] 49 comparator arm 49 RezularTM 49 visceral metastases 49 Traficet EN 49 arbaclofen 49 INTELENCE 49 carcinogenicity study 49 LCP Tacro TM 49 subcutaneous injection 49 rhGH 49 ritonavir boosting 49 dosing intervals 49 dose proportionality 49 glycopyrrolate 49 subcutaneous methylnaltrexone 48 LUMINATE 48 systemic corticosteroid 48 nebulization 48 thromboprophylaxis 48 XOMA 3AB 48 CALGB # [002] 48 stavudine d4T 48 interferon alfa 2b 48 fosamprenavir 48 Exherin TM 48 chemotherapy docetaxel 48 peak plasma concentrations 48 virological failure 48 mesalazine 48 insulin detemir 48 pharmacokinetic studies 48 subcutaneously injected 48 Phase 2a clinical trials 48 goserelin 48 tapentadol ER 48 Elitek 48 pimecrolimus 48 tolerability 48 ganciclovir 48 lopinavir r 48 indibulin 48 abacavir lamivudine 48 Fludara 48 Natroba 48 dirucotide 48 tipranavir 48 tanespimycin 48 ribavirin USP 48 lymph node dissection 48 Toremifene 48 HAART regimens 48 secondary efficacy endpoints 48 LB# [003] 48 IMiDs ® compound 48 posaconazole 48 PROSTVAC VF 48 Phase Ib clinical 48 dacetuzumab 48 dose escalation trial 48 RAPTIVA 48 BENICAR HCT 48 edifoligide E2F Decoy 48 palifermin 48 Telintra 48 paclitaxel Taxol 48 enzyme rHuPH# 48 LHRH agonist 48 PROMACTA 48 telaprevir VX 48 ENGAGE AF TIMI 48 LIALDA 48 cidofovir 48 Phase 2b study 48 peginterferon alfa 2a 48 PA# [002] 48 insulin degludec 48 lanreotide 48 decitabine 48 Cloretazine R 48 #mg BID [003] 48 SIMPADICO 48 opioid bowel dysfunction 48 randomized Phase IIb 48 mTOR inhibition 48 SEPET TM 48 Phase 2a trial 48 retapamulin 48 abacavir Ziagen 48 TNF alpha inhibitor 48 UVIDEM 48 BN# [004] 48 deferasirox 48 catheter insertion 48 prospectively stratified 48 ORENCIA ® 48 recurrent herpes labialis 48 cinacalcet 48 Phase 1a clinical 48 imexon 48 administered intramuscularly 48 registrational 48 randomisation 48 BoNTA 48 VersaFilm 48 PrevOnco ™ 48 release cysteamine bitartrate 48 QTc 48 Phase 1b clinical trials 48 Dacogen injection 48 oral antidiabetic medication 48 optimal dosing 48 beclomethasone dipropionate 48 phase IIa clinical 48 ZALBIN dosed 48 octreotide implant 48 dose proportional pharmacokinetics 48 NATRECOR R 48 Tekamlo 48 bronchodilation 48 AZT zidovudine Retrovir 48 MoxDuo 48 Cimzia TM 48 randomized Phase 2b 48 Rylomine TM 48 EmbraceAC 48 nonrandomized 48 miconazole Lauriad ® 48 Tindamax R 48 RRMS patients 48 idraparinux 47 nCPAP 47 budesonide pMDI 47 milrinone 47 Neulasta ® 47 oxycodone CR 47 GSK# [001] 47 GRNVAC1 47 Phase #/#a 47 mcg doses 47 samalizumab 47 imipenem 47 PEG Intron ® 47 REVIVE Diabetes 47 warfarin dosage 47 clinical trial 47 Apoptone 47 eszopiclone 47 mg q8h 47 virologic failure 47 Phase 1a 47 BETAS 47 interferon alfa 47 antiretroviral regimens 47 SPRYCEL ® 47 Study NX# 47 Zenvia ™ 47 randomized #:# 47 leukotriene modifiers 47 NRTI 47 Phase Ib IIa clinical 47 inhaled corticosteroid ICS 47 phase IIa 47 AMEVIVE 47 RISPERDAL ® 47 dosing regimen 47 pretransplant 47 pharmacodynamics 47 teduglutide 47 dosing frequency 47 pomalidomide 47 GOUT 47 FOSRENOL ® 47 FOLFOX chemotherapy 47 azelastine 47 acetazolamide 47 POSIDUR TM 47 idiopathic thrombocytopenic purpura 47 TACI Ig 47 Ventavis ® 47 cobiprostone 47 Phase III pivotal 47 Symadex 47 PANVAC VF 47 guanfacine extended release 47 LymphoStat B TM 47 Maximum Tolerated Dose 47 tropism testing 47 clotrimazole 47 sunitinib 47 CAELYX 47 PNP inhibitor 47 MVax 47 PRADAXA #mg 47 fluorouracil 47 Fodosine 47 transaminase 47 mupirocin 47 eniluracil 47 CUSTOM III 47 methylprednisolone 47 Zavesca R 47 bisoprolol 47 suppressive therapy 47 irbesartan 47 mg BID 47 recombinant follicle stimulating 47 palivizumab 47 visilizumab 47 LymphoStat B Phase 47 HER2 overexpression 47 CCR5 antagonist 47 lispro 47 lactulose 47 stated Michelle Berrey 47 nocturnal hypoglycaemia 47 CytoFabTM 47 intramuscularly 47 serum phosphate levels 47 REMINYL ® 47 herpetic keratitis 47 fibrotic disease 47 undetectable hepatitis C 47 pMDI 47 VAPRISOL 47 VICTRELIS 47 punctal plug 47 mealtime insulin 47 PRIMO CABG 47 bisphosphonate therapy 47 canakinumab 47 mcg dose 47 Phase 1b 47 Pentacel vaccine 47 Alzhemed TM 47 mcg mL 47 MMRV vaccine 47 administered orally 47 dopamine partial agonist 47 AIR# [001] 47 Phase IIb trials 47 torezolid phosphate 47 JAK2 V#F 47 urate lowering 47 midstage trials 47 adalimumab 47 oocytes retrieved 47 oral dosing regimen 47 intramuscular 47 Actimmune ® 47 peginterferon 47 1mg dose 47 intranasal formulation 47 olopatadine 46 genomic biomarker 46 Desferal 46 hemoglobin A1c levels 46 genotoxicity reproductive toxicology 46 dose escalation phase 46 ISENTRESS 46 hour bronchodilation 46 COPAXONE R 46 efficacy 46 insulin lispro 46 voriconazole 46 prucalopride 46 DermaVir Patch 46 brentuximab vedotin SGN 46 TYGACIL 46 oral amoxicillin 46 pharmacodynamic effects 46 vaginally administered lidocaine 46 achieved statistical significance 46 bowel resection 46 HBeAg 46 Hb levels 46 timolol 46 interferon beta 1b 46 CG# [003] 46 Phase 2b randomized 46 docetaxel 46 steroid dexamethasone 46 Symbicort SMART 46 MAXY alpha 46 BEXXAR 46 AKT inhibitor 46 PEG Intron 46 HDACi 46 intravenous infusion 46 oral PTH 46 NADiA ProsVue 46 EDEMA3 trial 46 NTx 46 pharmacokinetic PK profile 46 vaginal hysterectomy 46 phase Ib clinical 46 LANTUS R 46 treatment regimens 46 herpes zoster shingles 46 NEXTERONE 46 Urocidin TM 46 resminostat 46 heavily pretreated 46 peginterferon alpha 2a 46 Perforomist ™ Inhalation Solution 46 alpha blocker 46 PRECISE Trial 46 epoetin alfa 46 azilsartan medoxomil 46 Aclidinium 46 adipogenic 46 GED aPC 46 NVA# 46 cefazolin 46 seroconversion 46 ADAGIO study 46 mg eq 46 Phase IIb III 46 #I TM# 46 AIMM trial 46 CONCERTA 46 tolevamer 46 Eligen R B# 46 PEG SN# 46 clinicaltrials 46 PRECISE trial 46 PREZISTA ritonavir 46 polycythemia vera essential thrombocythemia 46 UPLYSO 46 mg doses 46 dexmedetomidine 46 Exforge HCT 46 SCENESSE ® 46 ZYVOX 46 pediatric pontine glioma 46 prazosin 46 leflunomide 46 divalproex sodium 46 piroxicam 46 mapatumumab 46 postapproval 46 edifoligide 46 serum phosphorus 46 sorafenib Nexavar 46 IIb clinical trial 46 #.#g/day 46 DSMB 46 Annamycin 46 darunavir ritonavir 46 Annexin V 46 trimethoprim sulfamethoxazole 46 tolterodine ER 46 intravenous bisphosphonates 46 orally administered inhibitor 46 non nucleoside HCV 46 mg m 46 OADs 46 LCP Tacro ™ 46 passaging 46 injectable formulations 46 Phase Ib 46 phase IIb 46 intravenous injection 46 EFFEXOR XR 46 mycophenolate mofetil 46 DDP# 46 JAK inhibitor 46 myeloproliferative diseases 46 palonosetron 46 antibiotic prophylaxis 46 renal toxicity 46 SAR# [004] 46 cangrelor 46 ponatinib 46 #mg/day [002] 46 GLP1 agonist 46 HCV viral 46 BROVANA 46 Phase 1b clinical 46 Hydroxyurea 46 DEXILANT 46 Apidra ® 46 ARCOXIA 46 antibody titer 46 griseofulvin 46 keloid scarring 46 tolvaptan 46 pharmacokinetic pharmacodynamic 46 dose colchicine 46 alagebrium 46 intravenous IV 46 EDEMA3 46 Cintredekin besudotox 46 BENICAR 46 exogenous insulin 46 HuLuc# 45 elotuzumab 45 pharmacokinetic 45 #.#mg 1mg 45 tecarfarin 45 ALVESCO 45 Phase IIIb 45 paricalcitol 45 epoprostenol 45 DXL# 45 Prodarsan 45 subcutaneous PRO 45 TKM ApoB 45 Lamictal XR 45 spontaneous bowel movements 45 Phase III psoriasis 45 serum phosphorus levels 45 Trofex 45 eptifibatide 45 Zoledronic acid 45 INFERGEN 45 Helixate FS 45 IAP inhibitor 45 EDARBI 45 pharmacodynamic properties 45 luteal 45 Amplimexon 45 vaginal lidocaine 45 sustained virologic response 45 cortical stimulation 45 mitoxantrone 45 motesanib diphosphate 45 PDE4 inhibitor 45 dermaPACE ™ 45 ARIKACE ™ 45 ANCHOR trial 45 Phase 2b kidney transplant 45 torsemide ER 45 pioglitazone HCl 45 PREOS R 45 Cytarabine Liposome Injection 45 cefprozil 45 PFO migraine 45 blood Phe 45 6mg 45 MERLIN TIMI 45 YONDELIS 45 9mg 45 lapatinib Tykerb 45 Diamyd r 45 ISTODAX 45 asthma exacerbations 45 e2 Collector 45 HQK 45 aztreonam 45 blinded randomized 45 Specifid 45 cobicistat 45 clevudine 45 levosimendan 45 cervical ripening 45 PI3K/Akt pathway inhibitor 45 Anturol TM 45 Known hypersensitivity 45 CLIRS 45 coadministration 45 Androxal TM 45 inhaled fluticasone 45 romidepsin 45 Urocidin 45 elevated transaminases 45 DURIN TM 45 nevirapine Viramune 45 neovascularisation 45 Lantus ® 45 efavirenz EFV 45 labetalol 45 atazanavir Reyataz 45 COPD exacerbations 45 Bicifadine 45 azacitidine 45 cefuroxime 45 AQUAVAN R 45 multiple myeloma MM 45 hepatic fibrosis 45 dual antiplatelet therapy 45 thrombin inhibiting aptamer 45 OVATURE 45 mg kg 45 S/GSK# 45 BCIRG 45 phase IIb III 45 alpha 2a 45 detemir 45 unboosted 45 ON #.Na 45 NPH insulin 45 Androgel R 45 Archexin 45 Phase Ia 45 endometrial adenocarcinoma 45 Akt inhibitor 45 Prograf R 45 treat dysmenorrhea 45 NMDA antagonist 45 huC# DM4 45 pegaptanib 45 CELVAPAN H#N# 45 Somatuline R Autogel R 45 torezolid 45 MEND CABG II 45 #mg/kg [002] 45 #mg dose [001] 45 ABC/3TC 45 TKM Ebola 45 miconazole 45 DiLA2 liposomes 45 detectable HCV RNA 45 octreotide acetate 45 5 HT3 receptor 45 prodromal symptoms 45 allogeneic stem cell 45 Cmax 45 pharmacokinetics 45 AZOR 45 Study #CL# 45 ritonavir boosted atazanavir 45 temozolomide 45 Tracleer R 45 undetectable HCV RNA 45 Thorough QT 45 mercaptopurine 45 EXJADE 45 titration regimen 45 calcipotriene 44 histamine dihydrochloride 44 monotherapy 44 Feasibility Trial 44 MIRAPEX ER 44 #mg/#mg 44 antiarrhythmic drugs 44 AZILECT R 44 QLT# 44 Flovent HFA 44 Pafuramidine 44 vivo toxicology 44 pentoxifylline 44 ciprofloxacin hydrochloride 44 oral mTOR inhibitor 44 HDL Selective Delipidation 44 #mg doses [002] 44 ALB # 44 VA# [002] 44 anticoagulation 44 oral antifungal 44 leuprorelin 44 HIV integrase inhibitors 44 DEEP AF 44 HCV antiviral 44 fumagillin nanoparticles 44 Virulizin R 44 ziprasidone 44 lorcaserin Phase 44 nimodipine 44 subcutaneously 44 mg RDEA# 44 NOXAFIL 44 squalamine 44 TRO# 44 Taxotere R 44 Plicera 44 Phase IIa clinical trials 44 RUGs IV 44 lorvotuzumab mertansine 44 EMBEDA ™ 44 chemosensitivity 44 Committee IDMC 44 Nanobodies 44 Excellagen 44 ONCONASE R 44 Indacaterol 44 REMICADE ® 44 PEP# [003] 44 recurrent endometrial cancer 44 PEP# Topical 44 lintuzumab